For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Total revenues | - | - | 69 | - |
| Total revenues | 86 | 117* | 100 | 202 |
| Research and development | 817 | 2,683* | 4,881 | 6,124 |
| General and administrative | 3,085 | 2,075* | 2,730 | 3,275 |
| Total operating expenses | 3,902 | 4,757* | 7,611 | 9,399 |
| Operating loss | -3,816 | -4,640* | -7,542 | -9,197 |
| Other income, net | 231 | -566* | 1,795 | 594 |
| Loss from continuing operations before income taxes | -3,585 | -5,207* | -5,747 | -8,603 |
| Income tax expense | 0 | 4* | 0 | - |
| Loss from continuing operations | -3,585 | -5,211* | -5,747 | -8,603 |
| Product sales, net-Product | - | 282* | - | - |
| General and administrative | - | 5 | - | - |
| Total operating expenses | - | 5* | - | - |
| Income (loss) from discontinued operations, before taxes | - | 277* | - | - |
| Income tax expense | - | 0* | - | - |
| Loss from discontinued operations, net of income taxes | 0 | 277* | -8 | -8 |
| Net loss | -3,585 | -4,934* | -5,755 | -8,611 |
| Unrealized gaines on marketable securities, net of tax of 0 | -2 | 15 | -2 | -20 |
| Total other comprehensive gain | -2 | 15* | -2 | -20 |
| Comprehensive loss | -3,587 | -4,919 | -5,757 | -8,631 |
| Basic EPS | -0.08 | -0.115 | -0.13 | -0.2 |
| Diluted EPS | -0.08 | -0.115 | -0.13 | -0.2 |
| Basic Average Shares | 42,768,000 | 42,872,000 | 42,759,000 | 42,673,000 |
| Diluted Average Shares | 42,768,000 | 42,872,000 | 42,759,000 | 42,673,000 |
VYNE Therapeutics Inc. (VYNE)
VYNE Therapeutics Inc. (VYNE)